Corcept Therapeutics Incorporated
NasdaqCM:CORT 株式レポート
Corcept Therapeutics マネジメント Corcept Therapeuticsの CEO はJoseph Belanoffで、 Jan1999年に任命され、 の在任期間は 25.83年です。 の年間総報酬は$ 9.34Mで、 11.6%給与と88.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.88%を直接所有しており、その価値は$ 180.13M 。経営陣と取締役会の平均在任期間はそれぞれ4年と23.1年です。
主要情報 CEO給与比率 11.6% CEO在任期間 25.8yrs CEOの所有権 2.9% 経営陣の平均在職期間 4yrs 取締役会の平均在任期間 23.1yrs
経営陣の近況
Chief Development Officer notifies of intention to sell stock Nov 04
Chief Business Officer & Secretary notifies of intention to sell stock Oct 03
Chief Development Officer notifies of intention to sell stock Sep 05
Co-Founder exercised options and sold US$9.2m worth of stock Aug 04
Chief Business Officer & Secretary notifies of intention to sell stock Jul 05
Chief Development Officer notifies of intention to sell stock May 30
すべての更新を表示
Investor sentiment improves as stock rises 16% Nov 06
Consensus EPS estimates increase by 21% Nov 06
Chief Development Officer notifies of intention to sell stock Nov 04
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 01
Corcept Therapeutics Incorporated Increases Earnings Guidance for the Year 2024 Oct 31
Corcept Therapeutics Incorporated to Report Q3, 2024 Results on Oct 30, 2024 Oct 24
Price target increased by 14% to US$74.64 Oct 18
Chief Business Officer & Secretary notifies of intention to sell stock Oct 03
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable Sep 28
Investor sentiment improves as stock rises 19% Sep 18
If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity Sep 06
Chief Development Officer notifies of intention to sell stock Sep 05
Consensus EPS estimates increase by 20% Aug 05
Co-Founder exercised options and sold US$9.2m worth of stock Aug 04
Price target increased by 20% to US$59.60 Aug 01
Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT) Aug 01
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Jul 30
Corcept Therapeutics Incorporated to Report Q2, 2024 Results on Jul 29, 2024 Jul 23
Chief Business Officer & Secretary notifies of intention to sell stock Jul 05
Price target increased by 14% to US$49.70 Jun 04
Chief Development Officer notifies of intention to sell stock May 30
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing’S Syndrome) May 29
President of Endocrinology notifies of intention to sell stock May 15
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 02
Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial Apr 30
Corcept Therapeutics Incorporated to Report Q1, 2024 Results on May 01, 2024 Apr 26
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis Apr 15
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For Apr 15
New minor risk - Shareholder dilution Apr 11
Corcept Therapeutics Incorporated, Annual General Meeting, May 17, 2024 Apr 11
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer Apr 10
Chief Accounting Officer notifies of intention to sell stock Apr 07
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome Apr 02
President of Endocrinology notifies of intention to sell stock Mar 29
President of Endocrinology exercised options and sold US$364k worth of stock Mar 21
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit Feb 22
Corcept Therapeutics: Key Catalysts Ahead Feb 19
President of Endocrinology notifies of intention to sell stock Feb 18
Full year 2023 earnings: EPS and revenues exceed analyst expectations Feb 16
Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial Feb 16
Corcept Therapeutics Incorporated to Report Q4, 2023 Results on Feb 15, 2024 Feb 09
Price target increased by 11% to US$39.60 Feb 04
New minor risk - Share price stability Jan 29
Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology Jan 29
Chief Scientific Officer exercised options and sold US$728k worth of stock Jan 14 Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024
Chief Development Officer notifies of intention to sell stock Dec 25
After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar Dec 23
President of Corcept Endocrinology notifies of intention to sell stock Dec 06
Consensus EPS estimates increase by 13% Nov 08
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price Nov 07
Price target increased by 8.1% to US$36.83 Nov 06
President of Corcept Endocrinology notifies of intention to sell stock Nov 03
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 02
Corcept Therapeutics Incorporated Appoints Monica Tellado as President, Emerging Markets Nov 02
Corcept Therapeutics Incorporated Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis Oct 27
Corcept Therapeutics Incorporated to Report Q3, 2023 Results on Nov 01, 2023 Oct 26
President of Corcept Endocrinology exercised options and sold US$452k worth of stock Oct 15
President of Corcept Endocrinology notifies of intention to sell stock Oct 04
Investor sentiment deteriorates as stock falls 16% Oct 02
President of Corcept Endocrinology notifies of intention to sell stock Sep 21
Chief Scientific Officer recently sold US$632k worth of stock Aug 17
Chief Scientific Officer exercised options and sold US$811k worth of stock Aug 10
Investor sentiment improves as stock rises 22% Aug 09
Price target increased by 7.3% to US$32.92 Aug 03
Corcept Therapeutics Incorporated to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Corcept Therapeutics Incorporated Publishes Results of Corcept’S Phase 2 Trial of Relacorilant in Women with Platinum-Resistant Ovarian Cancer Jun 28
Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value? Jun 23
Chief Accounting Officer notifies of intention to sell stock Jun 10
Chief Business Officer & Secretary recently sold US$1.1m worth of stock May 14
Chief Business Officer & Secretary exercised options and sold US$1.3m worth of stock May 11
Consensus EPS estimates fall by 21%, revenue upgraded May 10
First quarter 2023 earnings: EPS misses analyst expectations May 05
Corcept Therapeutics Incorporated Revises Revenue Guidance for 2023 May 05
Insufficient new directors Apr 02
Consensus EPS estimates fall by 21% Mar 07
Full year 2022 earnings: EPS misses analyst expectations Mar 02
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT) Feb 16
Price target decreased by 7.6% to US$31.60 Feb 16
Corcept Therapeutics Incorporated to Report Q4, 2022 Results on Feb 28, 2023 Feb 15
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation Feb 14
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today Jan 11
Corcept Therapeutics Provides Miricorilant Clinical Development Update Dec 09
Price target increased to US$35.00 Dec 05
Chief Business Officer & Secretary recently sold US$615k worth of stock Nov 23
President of Corcept Endocrinology exercised options and sold US$557k worth of stock Nov 17
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 04 Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2022 Nov 04
Corcept Therapeutics Incorporated to Report Q3, 2022 Results on Nov 03, 2022 Oct 29
Corcept Therapeutics Incorporated Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis Oct 12
Corcept Therapeutics starts phase 2 trial of its ALS treatment Oct 11
Chief Scientific Officer exercised options and sold US$719k worth of stock Oct 01
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist? Sep 27
CEO報酬分析 Corcept Therapeutics の収益と比較して、Joseph Belanoff の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Sep 30 2024 n/a n/a US$140m
Jun 30 2024 n/a n/a US$125m
Mar 31 2024 n/a n/a US$117m
Dec 31 2023 US$9m US$1m US$105m
Sep 30 2023 n/a n/a US$91m
Jun 30 2023 n/a n/a US$94m
Mar 31 2023 n/a n/a US$94m
Dec 31 2022 US$7m US$896k US$101m
Sep 30 2022 n/a n/a US$117m
Jun 30 2022 n/a n/a US$113m
Mar 31 2022 n/a n/a US$112m
Dec 31 2021 US$11m US$844k US$113m
Sep 30 2021 n/a n/a US$106m
Jun 30 2021 n/a n/a US$98m
Mar 31 2021 n/a n/a US$99m
Dec 31 2020 US$6m US$770k US$106m
Sep 30 2020 n/a n/a US$109m
Jun 30 2020 n/a n/a US$114m
Mar 31 2020 n/a n/a US$106m
Dec 31 2019 US$5m US$708k US$94m
Sep 30 2019 n/a n/a US$87m
Jun 30 2019 n/a n/a US$78m
Mar 31 2019 n/a n/a US$76m
Dec 31 2018 US$6m US$680k US$75m
Sep 30 2018 n/a n/a US$152m
Jun 30 2018 n/a n/a US$148m
Mar 31 2018 n/a n/a US$142m
Dec 31 2017 US$4m US$647k US$129m
報酬と市場: Josephの 総報酬 ($USD 9.34M ) は、 US市場 ($USD 7.88M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Josephの報酬は過去 1 年間で 20% 以上増加しました。
CEO（最高経営責任者 Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 Co-Founder 25.8yrs US$9.34m 2.88% $ 180.1m CFO & Treasurer 3.7yrs US$3.72m 0.012% $ 746.2k President of Endocrinology 8.6yrs US$3.91m 0.10% $ 6.3m Chief Development Officer 3.3yrs US$3.86m 0.0055% $ 345.3k Chief Business Officer & Secretary 10.8yrs US$3.96m 0.040% $ 2.5m Chief Accounting & Technology Officer 4.3yrs データなし 0.0095% $ 590.1k Chief Scientific Officer 4.3yrs US$3.11m 0.11% $ 7.1m Chief Human Resources & Communications Officer 3.3yrs データなし データなし President of Emerging Markets less than a year データなし データなし President of Oncology less than a year データなし データなし
もっと見る
経験豊富な経営陣: CORTの経営陣は 経験豊富 であると考えられます ( 4年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 Co-Founder 25.8yrs US$9.34m 2.88% $ 180.1m Independent Director 25.8yrs US$492.53k 5.07% $ 316.5m Independent Director 20.3yrs US$509.03k 1.25% $ 78.3m Member of Scientific Advisory Board no data データなし データなし Independent Chairman 25.8yrs US$1.26m 2.11% $ 132.0m Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし Independent Director 4.7yrs US$511.53k 0% $ 0 Member of Scientific Advisory Board no data データなし データなし Independent Director 5.2yrs US$488.53k 0% $ 0
もっと見る
経験豊富なボード: CORTの 取締役会 は経験豊富で 経験豊富 です ( 23.1年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
